Evidence map›Paper›PMID 35378910›Full record

ArticleEvidence-based complementary and alternative medicine : eCAM2022

Uncovering the Neuroprotective Effect of

Guozuo Wang, Xiaomei Zeng, Kailin Yang, Shengqiang Gong, Anqi Ge, Wenlong Liu, Qi He, Wenhao Zhang, Jinwen Ge

Open access · hybridAbstract read
In one paragraph

Article in Evidence-based complementary and alternative medicine : eCAM, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Guozuo WangHunan University of Chinese Medicine, Changsha, Hunan Province, China.ORCID https://orcid.org/0000-0002-3741-6478
Xiaomei ZengPeople's Hospital of Ningxiang City, Ningxiang City, Hunan Province, China.
Kailin YangHunan University of Chinese Medicine, Changsha, Hunan Province, China.ORCID https://orcid.org/0000-0002-1442-8644
Shengqiang GongHunan University of Chinese Medicine, Changsha, Hunan Province, China.
Anqi GeThe First Affiliated Hospital of Hunan University of Chinese Medicine, Changsha, Hunan Province, China.ORCID https://orcid.org/0000-0001-7193-8985
Wenlong LiuHunan University of Chinese Medicine, Changsha, Hunan Province, China.
Qi HeHunan University of Chinese Medicine, Changsha, Hunan Province, China.
Wenhao ZhangHunan University of Science and Technology, Xiang Tan, Hunan, China.
Jinwen GeHunan University of Chinese Medicine, Changsha, Hunan Province, China.ORCID https://orcid.org/0000-0003-4695-0012
Hunan University of Traditional Chinese Medicine · CNFirst Affiliated Hospital of Hunan University of Traditional Chinese Medicine · CNHunan University of Science and Technology · CNJiangxi Pingxiang People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To uncover the neuroprotective effect of Method: CI model was established by the modified Zea Longa intracavitary suture blocking method. After modeling, the rats were given intragastric administration for 7 days, once a day. After the 7-day intervention, the neurological function score was performed, the brain tissue was pathologically observed, and the total serum protein was extracted. Then, these proteins were analyzed by LC-MS/MS to identify the differentially expressed proteins (DEPs) in the HCC/CI group and CI/sham operation group. Finally, bioinformatics analysis was used to analyze DEPs, including gene ontology (GO) analysis, pathway analysis, and protein interaction analysis. ELISA and Western blotting were used to verify the proteomics results. Result: The neurological function scores of the HCC group were lower than those of the CI group. HE staining showed that the pathological results of the HCC group were improved. A total of 1340 proteins were identified by LC-MS/MS, of which 1138 proteins contain quantitative information. There are 122 DEPs in the CI/sham operation group and 25 DEPs in the HCC/CI group with fold change >1.3 or <0.77 and FDR<0.05. The 12 upregulated proteins in HCC/CI group include Protein Actn2, Kelch-like protein 41, Alpha-1, 4 glucan phosphorylase, Protein Lrtm2, Dystrophin, Galectin-1, and C4b-binding protein beta chain. The 13 downregulated proteins include Alpha-2 antiplasmin, Arachidonate 15-lipoxygenase, Carbonic anhydrase 2, Complement factor I, angiotensinogen, catalase, Protein LOC103691744, and Anionic trypsin-1. The bioinformatics analysis showed that HCC may treat CI through regulating cell-substrate adhesion and regulation, reactive oxygen species metabolic process, angiotensin response (cellular response to angiotensin), positive regulation of the occurrence of nerves and neurons (positive regulation of neurogenesis), inflammatory response, response to hypoxia (response to hypoxia, response to decreased oxygen levels), and cellular calcium homeostasis (cellular calcium ion homeostasis). The results of ELISA and Western blot also showed that, compared with model group, the angiotensinogen and catalase in HCC group were decreased ( Conclusion: The therapeutic mechanism of HCC in the treatment of CI may involve fibrinolysis, cell-matrix adhesion, inflammation, hypoxia, and oxidative stress.

Identifiers

PMID35378910
PMCPMC8976648
OpenAlexW4220777872

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.